BioComo

What BioComo does

BioComo Inc. is a privately held, R&D-stage biopharmaceutical company founded in May 2008 and headquartered in Komono, Mie Prefecture, Japan, with a co-located R&D office at Mie University in Tsu City. The company is built around a single core technology platform — BC-PIV (BioComo-Parainfluenza Virus), a non-propagative recombinant human parainfluenza virus type 2 (hPIV2) vector with the F membrane protein gene deleted, which is jointly developed and exclusively licensed from Mie University under the long-standing collaboration with Professor Tetsuya Nosaka. This vector is designed for safety (no secondary infectious virus production) while retaining high gene expression efficiency (~100x retrovirus per company data) and supports multi-gene inserts, surface antigen display, and intranasal mucosal delivery.

The company applies BC-PIV across two therapeutic verticals: (1) infectious disease vaccines, with lead candidates being ReSpiVec (intranasal RSV vaccine, in development with Mie University and contract-manufactured by Taiwan's TFBS Bioscience under AMED SCARDA funding) and a granted Japanese intranasal SARS-CoV-2 vaccine patent (No. 7825228), plus earlier-stage Ebola, Zika, and influenza candidates; and (2) anti-tumor immunotherapy, using BC-PIV vectors delivering TNFRSF ligands (OX40L, 4-1BBL, GITRL, CD27L, CD30L), cytokines, and chemokines against solid tumors, with a new US provisional patent application on CAF suppression filed May 2026 for cold-to-hot tumor conversion. Its business model is pre-commercial: revenue mechanics are research grants (AMED SCARDA), co-development arrangements with universities, and technology licensing/co-development partnerships with pharmaceutical counterparties — not product sales. The company's product portfolio and IP estate (patents granted in Japan, US, China, and EU, plus pending US filings) constitute its primary commercial assets, with global pharmaceutical licensing deals positioned as the eventual monetization path.

Name

BioComo

Legal name

バイオコモ株式会社

Website

https://biocomo.jp

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

BioComo is a pre-revenue Japanese biotech developing the BC-PIV viral vector platform, an hPIV2-based non-propagative system used for intranasal infectious disease vaccines (RSV, SARS-CoV-2) and anti-tumor immunotherapy, partnered with Mie University and AMED SCARDA.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Viral Vector & Vaccine Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Viral vector technology
• Biopharmaceutical R&D
• Intranasal vaccine platform
• Immunotherapy development
• Technology licensing

Headquarters

HQ city

Mie

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing: Pre-revenue R&D stage company generating income through licensing of BC-PIV vector technology platform to pharmaceutical partners, research institutions, and through co-development agreements for vaccine and immunotherapy development.
2. Co-development and Research Funding: Revenue from joint development partnerships with universities and government agencies such as AMED SCARDA for vaccine and immunotherapy R&D programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BioComo develops and licenses the proprietary BC-PIV Vector Technology — a non-propagative viral vector platform derived from human parainfluenza virus type 2 (hPIV2) — for use in intranasal infectious disease vaccines, anti-tumor immunotherapy, and next-generation adjuvants. The company is an R&D-stage biopharmaceutical firm that monetizes its platform through licensing, co-development partnerships with pharmaceutical companies, and government-funded research grants (e.g., AMED SCARDA), with products currently in pre-clinical to clinical development.

Product overview

BioComo offers the BC-PIV Vector Technology as its core platform—a non-propagative viral vector derived from human parainfluenza virus type 2 that enables both infectious disease vaccines and antitumor immunotherapy. The product portfolio includes: (1) BC-PIV Vector Technology as the foundational platform; (2) SARS-CoV-2 Vaccine (BC-PIV/S2PM), an intranasal COVID-19 vaccine with granted Japanese patent; (3) ReSpiVec, an intranasal RSV vaccine candidate; (4) Anti-tumor Immunotherapy Agent using BC-PIV vector with TNFRSF ligands and cytokines; and (5) Next-Generation Adjuvant Technology. The platform is applied to both nasal spray vaccines and tumor immunotherapy agents targeting cold-to-hot tumor conversion.

Differentiator

Problem solved

Functional benefit

Products and services

• BC-PIV Vector Technology Proprietary non-propagative viral vector platform derived from human parainfluenza virus type 2 (hPIV2) with F protein gene deleted for safety. Enables gene delivery, vaccine development, and immunotherapy applications with high gene expression efficiency and repeated dosing capability. Offered for licensing and co-development to pharmaceutical partners and research institutions.
• SARS-CoV-2 Vaccine (BC-PIV/S2PM) Intranasal spray vaccine using BC-PIV vector to deliver trimeric spike protein of SARS-CoV-2, providing infection protection in both lungs and nasal cavity. Patent granted in Japan (Patent No. 7825228, February 2026). Pre-commercial.
• ReSpiVec (RSV Vaccine) Intranasal spray vaccine candidate for Respiratory Syncytial Virus using BC-PIV vector with DS-Cav1 antigen, targeting both elderly and infant populations. Under joint development with Mie University and TFBS Bioscience, funded by AMED SCARDA. Pre-commercial.
• Anti-tumor Immunotherapy Agent (BC-PIV) Oncology treatment using BC-PIV vector to deliver cytokines (IL-2, IL-7, IL-12, IL-15, GM-CSF), chemokines (CCL19, CCL21), and TNFRSF ligands (OX40L, 4-1BBL, GITRL, CD27L, CD30L) for immune activation against solid tumors. Patent granted (Patent No. 7398680, 2019). Pre-clinical to early development.
• Next-Generation Adjuvant Technology Vaccine adjuvant technology developed jointly with Mie University that mimics viral structure to safely and effectively activate immune responses using smaller antigen quantities with reduced side effects. Patent granted (Patent No. 6709488, 2015).

Quantifiable outcome

• 100x higher protein expression compared to retrovirus systems
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered secondary, key and core.

• Tokyo University (東京大学)secondaryStrategic or Co-development Partner · 26 February 2026Joint patent filing partner for SARS-CoV-2 vaccine technology. Co-applicant with BioComo and Mie University for Patent No. 7825228 (BC-PIV nasal vaccine).
• BC-PIV Cancer Consortium (抗腫瘍免疫剤開発コンソーシアム)keyStrategic or Co-development Partner · 1 July 2024Clinical consortium established July 2024 for anti-tumor agent development. Includes physicians and researchers from various fields working with BioComo on BC-PIV immunotherapy. Ensures clinical relevance and up-to-date knowledge integration in development.
• TFBS Bioscience Inc. (台湾)keyTechnology or Integration · 25 April 2024Contract manufacturing partner for RSV vaccine development. Selected for virus vector vaccine manufacturing process development, production, quality testing, and safety testing following international guidelines. First viral vector CDMO in Taiwan, established 2016. Provides end-to-end services for gene and cell therapy clinical trials.
• Rockefeller University / Prof. Moriya TsujisecondaryStrategic or Co-development Partner · 1 September 2015Prof. Moriya Tsuji (MD, PhD, Professor, The Aaron Diamond AIDS Research Center, Rockefeller University) appointed as BioComo advisor in September 2015. Expertise in immunology and vaccine research.
• Japan National Institute of Biomedical Innovation (医薬基盤研究所)secondaryStrategic or Co-development Partner · 1 December 2013Three-party joint research agreement signed August 2009 for PIV2-based pharmaceutical development. Research foundation supporting biotech innovation in Japan.
• Mie University (三重大学)coreStrategic or Co-development Partner · 1 May 2008Founding strategic partner. BC-PIV vector technology originally developed at Mie University and exclusively licensed. Ongoing joint development including RSV nasal spray vaccine clinical trials, anti-tumor immunotherapy R&D. Professor Tetsuya Nosaka leads research collaboration. Strong partnership since company founding in May 2008.

Scale indicators4 records

Recent moves4 records

Expansion highlights6 records

Direct peers

• Meissa Vaccines: Private US biotech developing live-attenuated intranasal vaccines for RSV and other respiratory viruses. Direct competitor in the intranasal RSV vaccine space, with similar mucosal immunity approach using attenuated viral vectors.
• Altimmune: US clinical-stage biotech focused on intranasal vaccines (NasoShield, T-COVID, FluCOVID) and liver disease therapeutics. Directly comparable intranasal vaccine modality targeting similar respiratory indications as BioComo's BC-PIV platform.
• BlueWillow Biologics: US biotech developing intranasal vaccines and therapeutics using novel nanoemulsion technology. Compares to BioComo in pursuing intranasal respiratory vaccines and mucosal immunity approaches for infectious disease prevention.
• Codagenix: Private US biotech using codon deoptimization to develop live-attenuated intranasal vaccines for RSV, influenza, and other respiratory pathogens. Directly comparable intranasal vaccine platform targeting overlapping indications with BioComo.
• Vaxart: Clinical-stage US biotech developing oral tablet vaccines using adenoviral vector platform to induce mucosal immunity. Shares BioComo's strategy of using viral vectors to deliver mucosal immunity against respiratory pathogens, though using oral rather than intranasal delivery.

Broad incumbents

• Takara Bio: Established Japanese biotech subsidiary of Takara Holdings specializing in viral vectors, gene therapy, and cell therapy products and CDMO services. Larger incumbent operating in the same viral vector space as BioComo with broader portfolio and manufacturing scale.
• uniQure: Netherlands-based gene therapy company developing AAV-based therapies with approved hemophilia B product. Compares as established viral vector gene therapy developer with similar CMC and regulatory infrastructure, though using AAV rather than hPIV2 vectors.
• AnGes: Japanese biotech developing DNA vaccines and gene therapies, with approved HGF gene therapy product. Comparable as Japanese gene therapy/biologics developer, though using different (DNA-based) platform technology than BioComo's viral vector.

Emerging players

• Intravacc: Dutch viral vector vaccine development and CDMO organization developing intranasal vaccines and polio vaccines. Comparable as a specialized viral vector platform developer with both R&D and manufacturing capabilities.
• Icosavax: US biotech developing VLP-based vaccines with lead RSV candidate (IVX-A12) for older adults. Targets the same RSV market opportunity as BioComo's ReSpiVec, though using VLP rather than viral vector technology.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioComo